SC
VIR icon

Steven Cohen’s Vir Biotechnology VIR Stock Holding History

Steven Cohen’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-69,900
Closed -$1.71M – 2904
2023
Q2 		$1.71M Buy
+69,900
New +$1.76M 0.01% 1065

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Steven Cohen's VIR Position: Q2 2026 in Review

Steven Cohen increased its Vir Biotechnology (VIR) stake by 190% in Q2 2026, buying an estimated $35.3M and bringing the position to 5,666,821 shares worth $57.7M. The position accounts for 0.06% of the portfolio, ranked #376.

Steven Cohen first reported a position in VIR in Q3 2021 and has held it in 14 quarters since. The position peaked at $86M in Q4 2021. 236 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Steven Cohen held 5,666,821 shares of Vir Biotechnology worth $57.7M as of Q2 2026.
  • Steven Cohen bought 3,714,587 Vir Biotechnology shares in Q2 2026, an estimated $35.3M.
  • Vir Biotechnology made up 0.06% of Steven Cohen's portfolio in Q2 2026, its #376 holding.
  • Steven Cohen first reported a position in Vir Biotechnology in Q3 2021 and has held it in 14 quarters since.
  • Steven Cohen's Vir Biotechnology position peaked at $86M in Q4 2021.
  • 236 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.